1. Home
  2. SCNX vs NEUP Comparison

SCNX vs NEUP Comparison

Compare SCNX & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scienture Holdings Inc.

SCNX

Scienture Holdings Inc.

HOLD

Current Price

$0.39

Market Cap

18.4M

Sector

Health Care

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$3.99

Market Cap

21.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCNX
NEUP
Founded
2010
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.4M
21.7M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
SCNX
NEUP
Price
$0.39
$3.99
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
604.9K
31.1K
Earning Date
03-25-2026
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$653,391.00
$15,649,448.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
207.88
N/A
52 Week Low
$0.42
$3.65
52 Week High
$3.61
$21.40

Technical Indicators

Market Signals
Indicator
SCNX
NEUP
Relative Strength Index (RSI) 32.23 48.50
Support Level $0.42 $3.94
Resistance Level $0.48 $4.09
Average True Range (ATR) 0.03 0.10
MACD -0.00 0.01
Stochastic Oscillator 6.78 45.83

Price Performance

Historical Comparison
SCNX
NEUP

About SCNX Scienture Holdings Inc.

Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: